我们即将找到治疗 1 型糖尿病的突破性疗法,但谁是 200 万美国患者?

Rebecca A Smith, Samara Eisenberg, Aaron Turner-Pfifer, Jacqueline Le Grand, Sarah Pincus, Yousra Omer, Fei Wang, Bruce Pyenson
{"title":"我们即将找到治疗 1 型糖尿病的突破性疗法,但谁是 200 万美国患者?","authors":"Rebecca A Smith, Samara Eisenberg, Aaron Turner-Pfifer, Jacqueline Le Grand, Sarah Pincus, Yousra Omer, Fei Wang, Bruce Pyenson","doi":"10.1101/2024.07.24.24310877","DOIUrl":null,"url":null,"abstract":"Two million Americans have Type 2 Diabetes. Innovative treatments have standardized insulin delivery and improved outcomes for patients, but patients' access to such technologies depends on social determinants of health, including insurance coverage, proper diagnosis, and appropriate patient supports. Prior estimates of US prevalence, incidence, and patient characteristics have relied on data from select regions and younger ages and miss important determinants. By contrast, our research leveraged nationally representative administrative claims datasets to build a nuanced picture of the population with T1DM. Our work also supports future policy and research efforts with 2025, 2029, and 2035 projections of demographic and insurance coverage for people with T1DM.","PeriodicalId":501386,"journal":{"name":"medRxiv - Health Policy","volume":"68 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It?\",\"authors\":\"Rebecca A Smith, Samara Eisenberg, Aaron Turner-Pfifer, Jacqueline Le Grand, Sarah Pincus, Yousra Omer, Fei Wang, Bruce Pyenson\",\"doi\":\"10.1101/2024.07.24.24310877\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Two million Americans have Type 2 Diabetes. Innovative treatments have standardized insulin delivery and improved outcomes for patients, but patients' access to such technologies depends on social determinants of health, including insurance coverage, proper diagnosis, and appropriate patient supports. Prior estimates of US prevalence, incidence, and patient characteristics have relied on data from select regions and younger ages and miss important determinants. By contrast, our research leveraged nationally representative administrative claims datasets to build a nuanced picture of the population with T1DM. Our work also supports future policy and research efforts with 2025, 2029, and 2035 projections of demographic and insurance coverage for people with T1DM.\",\"PeriodicalId\":501386,\"journal\":{\"name\":\"medRxiv - Health Policy\",\"volume\":\"68 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Health Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.07.24.24310877\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Health Policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.07.24.24310877","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

有 200 万美国人患有 2 型糖尿病。创新疗法规范了胰岛素的给药方式,改善了患者的治疗效果,但患者能否获得这些技术取决于健康的社会决定因素,包括保险范围、正确诊断和适当的患者支持。之前对美国患病率、发病率和患者特征的估计依赖于特定地区和较低年龄段的数据,忽略了重要的决定因素。相比之下,我们的研究利用了具有全国代表性的行政报销数据集,对患有 T1DM 的人群进行了细致入微的描述。我们的研究还通过对 2025 年、2029 年和 2035 年 T1DM 患者的人口和保险覆盖率的预测,为未来的政策和研究工作提供了支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It?
Two million Americans have Type 2 Diabetes. Innovative treatments have standardized insulin delivery and improved outcomes for patients, but patients' access to such technologies depends on social determinants of health, including insurance coverage, proper diagnosis, and appropriate patient supports. Prior estimates of US prevalence, incidence, and patient characteristics have relied on data from select regions and younger ages and miss important determinants. By contrast, our research leveraged nationally representative administrative claims datasets to build a nuanced picture of the population with T1DM. Our work also supports future policy and research efforts with 2025, 2029, and 2035 projections of demographic and insurance coverage for people with T1DM.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信